Gain Therapeutics, Inc. (NASDAQ:GANX) Shares Sold by Gotham Asset Management LLC

Gotham Asset Management LLC cut its holdings in shares of Gain Therapeutics, Inc. (NASDAQ:GANX - Free Report) by 52.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 158,155 shares of the company's stock after selling 176,437 shares during the quarter. Gotham Asset Management LLC owned 0.60% of Gain Therapeutics worth $342,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of GANX. Sprott Inc. acquired a new stake in shares of Gain Therapeutics in the fourth quarter worth $30,000. Benedict Financial Advisors Inc. purchased a new stake in Gain Therapeutics in the fourth quarter valued at $35,000. Bridgeway Capital Management LLC acquired a new stake in Gain Therapeutics during the 4th quarter worth about $65,000. Northern Trust Corp raised its stake in shares of Gain Therapeutics by 88.2% during the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company's stock valued at $183,000 after buying an additional 39,642 shares during the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of Gain Therapeutics in the 4th quarter valued at about $198,000. 11.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently commented on GANX. Chardan Capital reaffirmed a "buy" rating and set a $6.00 target price on shares of Gain Therapeutics in a report on Friday, March 28th. Scotiabank initiated coverage on Gain Therapeutics in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $12.00 price objective on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and set a $8.00 price objective on shares of Gain Therapeutics in a research note on Monday, May 19th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $8.20.

Gain Therapeutics Price Performance

Shares of GANX stock traded up $0.01 during mid-day trading on Monday, hitting $1.80. 72,466 shares of the stock were exchanged, compared to its average volume of 311,633. Gain Therapeutics, Inc. has a 52-week low of $0.89 and a 52-week high of $3.19. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04. The company has a market cap of $53.20 million, a PE ratio of -1.64 and a beta of 0.17. The firm has a fifty day moving average of $1.89 and a 200 day moving average of $1.99.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.16) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.16). Research analysts anticipate that Gain Therapeutics, Inc. will post -1 earnings per share for the current year.

Gain Therapeutics Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.